Skip to main content

Table 2 Patient characteristics (all patients, N = 421)

From: Morning and evening behavior in children and adolescents treated with atomoxetine once daily for Attention-Deficit/Hyperactivity Disorder (ADHD): Findings from two 24-week, open-label studies

Demographics

 

   Boys, N (%)

338 (80.3)

   Girls, N (%)

83 (19.7)

   Age [years], mean (± SD)

11.1 (2.7)

ADHD subtype, N (%)

 

   Combined

278 (66.0)

   predominantly inattentive

124 (29.5)

   predominantly hyperactive-impulsive

6 (1.4)

   ADHD, not otherwise specified

13 (3.1)

Most frequent psychiatric comorbidities, N (%)

 

   Conduct disorder

83 (19.7)

   Oppositional defiant disorder

74 (17.6)

   Enuresis

18 (4.3)

   Emotional disorder of childhood

11 (2.6)

   Tic disorder

10 (2.4)

   Depression

6 (1.4)

   Depressed mood

5 (1.2)

Baseline disease characteristics, mean (± SD)

 

   ADHD-RS, total score

32.6 (10.9)

   CGI-Severity (of ADHD)

5.0 (0.8)

   WREMB-R, total score

18.0 (7.0)

   GIPD, total score patient-rated

13.1 (5.8)

   GIPD, total score parent-rated

18.6 (6.1)

   GIPD, total score physician-rated

20.3 (5.9)

  1. Abbreviations: ADHD = Attention deficit/hyperactivity disorder, ADHD-RS = ADHD Rating Scale (parent-rated, investigator-administered and scored), CGI-Severity = Clinical Global Impression, Severity, GIPD = Global Impression of perceived difficulties, SD = standard deviation, WREMB-R = Weekly Ratings of Evening and Morning Behavior-Revised